DalsnaFinance

Ginkgo Bioworks Holdings Inc Class $DNA

Health Care

Russell 2000 Massachusetts
Create a scorecard
$10.14
+0.07 (+0.70%)
As of Oct 20, 2026, 2:10 PM EDT
Price history
Loading chart…

Ginkgo Bioworks Holdings Inc Class (DNA) is trading up at $10.14 (+0.70%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

Ginkgo Bioworks Holdings Inc Class revenue & net income history (FY2019–FY2025)

RevenueNet incomeNet margin (right axis, %)
$477.7M−$813.6M−$2.10BFY2019 revenue: $54.2MFY2019 net income: −$119.3M · Net margin −220.2%'19FY2020 revenue: $76.7MFY2020 net income: −$126.6M · Net margin −165.2%'20FY2021 revenue: $313.8MFY2021 net income: −$1.83B · Net margin −583.1%'21FY2022 revenue: $477.7MFY2022 net income: −$2.10B · Net margin −440.6%'22FY2023 revenue: $251.5MFY2023 net income: −$892.9M · Net margin −355.1%'23FY2024 revenue: $227.0MFY2024 net income: −$547.0M · Net margin −240.9%'24FY2025 revenue: $170.2MFY2025 net income: −$312.8M · Net margin −183.8%'25−100%−75%−50%−25%0%FY2019 net margin: −220.2% (off the scale, which stops at −100.0%)FY2020 net margin: −165.2% (off the scale, which stops at −100.0%)FY2021 net margin: −583.1% (off the scale, which stops at −100.0%)FY2022 net margin: −440.6% (off the scale, which stops at −100.0%)FY2023 net margin: −355.1% (off the scale, which stops at −100.0%)FY2024 net margin: −240.9% (off the scale, which stops at −100.0%)FY2025 net margin: −183.8% (off the scale, which stops at −100.0%)
Ginkgo Bioworks Holdings Inc Class annual financial statements
FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$54.2M$76.7M$313.8M$477.7M$251.5M$227.0M$170.2M
Growth (year over year)—+41.5%+309.4%+52.2%−47.4%−9.7%−25.1%
Operating income−$71.6M−$137.0M−$1.83B−$2.21B−$864.4M−$559.8M−$315.3M
Operating margin−132.1%−178.8%−582.6%−462.4%−343.8%−246.5%−185.3%
Net income−$119.3M−$126.6M−$1.83B−$2.10B−$892.9M−$547.0M−$312.8M
Net margin−220.2%−165.2%−583.1%−440.6%−355.1%−240.9%−183.8%
EPS (diluted)−$4.00−$4.00−$55.60−$50.20−$18.37−$10.54−$5.64
Balance sheet
Cash and equivalents$495.3M$380.8M$1.55B$1.32B$944.1M$561.6M$167.2M
Total assets—$675.2M$2.07B$2.54B$1.67B$1.38B$1.12B
Total liabilities—$205.1M$503.6M$803.0M$568.2M$661.4M$611.1M
Shareholders' equity$501.9M$461.4M$1.51B$1.74B$1.10B$716.1M$508.6M
Cash flow
Operating cash flow−$44.7M−$135.8M−$253.8M−$252.2M−$295.5M−$319.6M−$171.1M
Capital expenditure$22.2M$57.8M$56.5M$52.3M$40.8M$62.5M$7.67M
Free cash flow−$66.9M−$193.7M−$310.3M−$304.5M−$336.3M−$382.1M−$178.7M
Share buybacks$408.0K——————

From Ginkgo Bioworks Holdings Inc Class's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Ginkgo Bioworks Holdings Inc Class

Headquarters
Boston, Massachusetts From SEC filings, Oct 2026

Recent News (15)

More Health Care stocks

Browse all companies →